The trial I was trying to get my relative in had just 10% as many people signed up at Stanford as at Modesto.
It may be a bit dated, but Kaiser has COVID-19 research studies.
On Nov. 23, Operation Warp Speed listed a number of therapeutics that had been distributed across the country.
"The investigational monoclonal antibody therapeutic cocktail of casirivimab and imdevimab, [EUA Nov. 21] from drug maker Regeneron, is not for COVID-19 patients who are already hospitalized, but instead for patients who have mild to moderate COVID-19 symptoms and who are at high risk of disease progression." 30K doses distributed initially (Nov 24). I believe 300K doses were purchased.
By Dec. 15, over 5700 courses have been distributed to California. Over 38K have been delivered to the country.
"With bamlanivimab, [another monoclonal antibody] distribution is now in the third week [EUA Nov 9]. Already, Redd said, more than 120,000 patient courses for that drug have been allocated across the nation, and over 85,000 patient courses of bamlanivimab have been delivered to nearly 2,500 care sites across the nation."
By Dec. 15, nearly 200K courses have been distributed.
Let me emphasize that you don't need to have a bad case of COVID to get these therapeutics. If you wait that long, you may be out of luck.
It may be a bit dated, but Kaiser has COVID-19 research studies.
On Nov. 23, Operation Warp Speed listed a number of therapeutics that had been distributed across the country.
"The investigational monoclonal antibody therapeutic cocktail of casirivimab and imdevimab, [EUA Nov. 21] from drug maker Regeneron, is not for COVID-19 patients who are already hospitalized, but instead for patients who have mild to moderate COVID-19 symptoms and who are at high risk of disease progression." 30K doses distributed initially (Nov 24). I believe 300K doses were purchased.
By Dec. 15, over 5700 courses have been distributed to California. Over 38K have been delivered to the country.
"With bamlanivimab, [another monoclonal antibody] distribution is now in the third week [EUA Nov 9]. Already, Redd said, more than 120,000 patient courses for that drug have been allocated across the nation, and over 85,000 patient courses of bamlanivimab have been delivered to nearly 2,500 care sites across the nation."
By Dec. 15, nearly 200K courses have been distributed.
Let me emphasize that you don't need to have a bad case of COVID to get these therapeutics. If you wait that long, you may be out of luck.